company overview


George Farmer, Ph.D.
Chief Executive Officer

Dr. Farmer most recently served as Vice President, Corporate Development at Synta Pharmaceuticals, a biotechnology company developing oncology therapeutics. As a Senior Equity Analyst with Canaccord Genuity, Wachovia Securities, and Fortis Bank, Dr. Farmer covered a wide range of companies developing and commercializing drugs for many different therapeutic indications. Prior to his career as an analyst, Dr. Farmer served as a Senior Scientist at DuPont Pharmaceuticals Company and completed post-doctoral fellowships at Memorial Sloan Kettering Cancer Center and University of California San Francisco investigating molecular mechanisms of cancer progression. Dr. Farmer received his Ph.D. in Biological Sciences from Columbia University and a B.A. from Dartmouth College.

Donald Picker, Ph.D.
Chief Operating Officer

Dr. Picker led the Biomedical Division of Johnson Matthey, where his group was responsible for the discovery and initial clinical development of carboplatin, a major drug in cancer treatment. Dr. Picker went on to Genta. Inc. as Executive Vice President of research and development, where he was responsible for establishing the cancer program and bringing Genesense into the clinic. He went on to become the President of LXR Biotechnology, which focused on apoptosis inhibitors in the CNS and cardiovascular therapeutic areas.  As CEO of Synergy Pharmaceuticals, Dr. Picker brought a hepatitis drug into clinical development and built a cancer company that was merged into Callisto Pharmaceuticals. As Executive Vice President of Research and Development at Callisto he licensed in other cancer programs and brought two drugs into clinical development. Dr Picker was also a founder of Xenimics, a DNA diagnostic company and FermaVir, an infectious disease company recently merged into Inhibitex.  Dr. Picker received a Ph.D. in organic chemistry from SUNY Albany, and completed post-doctoral studies at the University of Washington and Schering.

Sandra Silberman, M.D.

Dr. Silberman began her career in clinical development at Pfizer, Inc., where she initiated the Company's first program in clinical oncology and oversaw the introduction of Tarceva into clinical trials. She then served as Senior Director for Novartis Clinical Research, where she led the global development of Gleevec. Dr. Silberman subsequently joined Eisai Medical Research as Vice President and Global Therapeutic Area Head (oncology), a role in which she advanced six novel compounds into Phases I,II and III clinical development. Following this she served as the Chief Medical Officer for Tapestry Pharmaceuticals, creating and implementing a global clinical trial development program for TPI 287. As an independent industry consultant over the years, Dr. Silberman has advised Bristol-Myers Squibb, AstraZeneca, Imclone, Roche, and GPC-Biotech on their various oncology programs.  Dr. Silberman received a B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively.  She received her M.D. from Cornell University Medical College. She completed a fellowship in hematology/oncology at the Brigham & Women's and the Dana Farber Cancer Institute in Boston, and was an Instructor in Medicine at Harvard Medical School.  Dr. Silberman is board certified in Internal Medicine and Hematology.